J. Litchfield

发表

Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose.

J. Baynes, S. Thorpe, K. Wells-Knecht, 1995, Biochemistry.

New biomarkers of Maillard reaction damage to proteins.

J. Baynes, S. Thorpe, M. Wells-Knecht, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

B. Feng, T. Goosen, Y. Lai, 2012, Pharmaceutical Research.

Effect of Hepatic Organic Anion‐Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver‐Targeted Glucokinase Activator: A Model‐Based Evaluation

J. Pfefferkorn, D. Kazierad, M. Varma, 2019, Clinical pharmacology and therapeutics.

Structural attributes influencing unbound tissue distribution.

Christopher E. Keefer, A. Kalgutkar, D. Scott, 2019, European journal of medicinal chemistry.

AGE-breakers cleave model compounds, but do not break Maillard crosslinks in skin and tail collagen from diabetic rats.

J. Baynes, J. Litchfield, Shengzu Yang, 2003, Archives of biochemistry and biophysics.

Global Portrait of Protein Targets of Metabolites of the Neurotoxic Compound BIA 10-2474.

B. Cravatt, A. Cognetta, J. Litchfield, 2019, ACS chemical biology.

Physicochemical Property Space of Hepatobiliary Transport and Computational Models for Predicting Rat Biliary Excretion

B. Feng, T. Goosen, Y. Lai, 2012, Drug Metabolism and Disposition.

Novel Method to Predict In Vivo Liver-to-Plasma Kpuu for OATP Substrates Using Suspension Hepatocytes

L. Di, J. Litchfield, Jian Lin, 2017, Drug Metabolism and Disposition.

Response to the Comment on the Article “Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions”

B. Feng, T. Goosen, Y. Lai, 2013, Pharmaceutical Research.

Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver

J. Litchfield, H. Eng, S. Mathialagan, 2020, The AAPS Journal.

Pyridones as glucokinase activators: identification of a unique metabolic liability of the 4-sulfonyl-2-pyridone heterocycle.

J. Pfefferkorn, P. Oates, J. Litchfield, 2009, Bioorganic & medicinal chemistry letters.

The design and synthesis of indazole and pyrazolopyridine based glucokinase activators for the treatment of type 2 diabetes mellitus.

Michael D. Hamilton, J. Pfefferkorn, N. Barucci, 2012, Bioorganic & medicinal chemistry letters.

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

M. Ammirati, J. Treadway, S. Liras, 2011 .

Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.

A. Carlo, J. Pfefferkorn, J. Litchfield, 2013, Bioorganic & medicinal chemistry letters.

Optimizing glucokinase activator binding kinetics to lower in vivo hypoglycemia risk

T. Rolph, J. Pfefferkorn, K. Borzilleri, 2014 .

DMD058032 1599..1610

T. Maurer, A. Ghosh, D. Scott, 2014 .

OATP1B1/1B3-mediated hepatic uptake determines the pharmacokinetics of large lipophilic acids: In vitro–in vivo evaluation in cynomolgus monkey

A. Kalgutkar, M. Varma, J. Litchfield, 2021 .

Design and synthesis of potent, orally-active DGAT-1 inhibitors containing a dioxino[2,3-d]pyrimidine core.

M. Munchhof, J. Litchfield, K. Karki, 2011, Bioorganic & medicinal chemistry letters.

Transporter-Enzyme Interplay in the Pharmacokinetics of PF-06835919, a First-In-Class Ketohexokinase Inhibitor for Metabolic Disorders and Nonalcoholic Fatty Liver Disease

A. D. Rodrigues, A. Kalgutkar, L. Di, 2022, Drug Metabolism and Disposition.

Effect of a Ketohexokinase Inhibitor (PF‐06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug

A. D. Rodrigues, M. Varma, A. Bergman, 2022, Clinical pharmacology and therapeutics.

Metabolites in Safety Testing Assessment in Early Clinical Development: A Case Study with a Glucokinase Activator

W. S. Denney, A. Kalgutkar, J. Pfefferkorn, 2014, Drug Metabolism and Disposition.

The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.

J. Treadway, J. Pfefferkorn, W. Zavadoski, 2013, Bioorganic & medicinal chemistry letters.

Target occupancy study and whole-body dosimetry with a MAGL PET ligand [11C]PF-06809247 in non-human primates

R. Carson, C. Halldin, A. Takano, 2021, EJNMMI Research.

Pharmacokinetics and Toxicokinetics in Drug Discovery and Development

M. Varma, J. Litchfield, Z. Radi, 2012 .

Intrinsic electrophilicity of the 4-methylsulfonyl-2-pyridone scaffold in glucokinase activators: role of glutathione-S-transferases and in vivo quantitation of a glutathione conjugate in rats.

S. Wright, A. Kalgutkar, J. Pfefferkorn, 2010, Bioorganic & medicinal chemistry letters.

Oxygen is not required for the browning and crosslinking of protein by pentoses: relevance to Maillard reactions in vivo.

J. Baynes, S. Thorpe, J. Litchfield, 1999, The international journal of biochemistry & cell biology.

A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity.

S. Wright, J. Pfefferkorn, J. Litchfield, 2012, Bioorganic & medicinal chemistry letters.

Discovery of novel hepatoselective HMG-CoA reductase inhibitors for treating hypercholesterolemia: a bench-to-bedside case study on tissue selective drug distribution.

Bo Feng, David B Duignan, Bruce Auerbach, 2011, Bioorganic & medicinal chemistry letters.

N-benzylimidazole carboxamides as potent, orally active stearoylCoA desaturase-1 inhibitors.

C. Steppan, J. Litchfield, R. Trilles, 2011, Bioorganic & medicinal chemistry letters.

Toward a Unified Model of Passive Drug Permeation II: The Physiochemical Determinants of Unbound Tissue Distribution with Applications to the Design of Hepatoselective Glucokinase Activators

T. Maurer, A. Ghosh, D. Scott, 2014, Drug Metabolism and Disposition.

Medicinal chemistry design principles for liver targeting through OATP transporters.

A. Mathiowetz, S. Liras, J. Pfefferkorn, 2013, Current topics in medicinal chemistry.

Targeting intestinal transporters for optimizing oral drug absorption.

M. Varma, J. Litchfield, M. Ullah, 2010, Current drug metabolism.

Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis.

David A. Price, A. Kalgutkar, K. Beaumont, 2018, Journal of medicinal chemistry.

Quantitative Prediction of Human Renal Clearance and Drug-Drug Interactions of Organic Anion Transporter Substrates Using In Vitro Transport Data: A Relative Activity Factor Approach

Bo Feng, B. Feng, M. Varma, 2017, Drug Metabolism and Disposition.

The Relationship of Glucokinase Activator–induced Hypoglycemia with Arteriopathy, Neuronal Necrosis, and Peripheral Neuropathy in Nonclinical Studies

Bradley E. Enerson, J. Pfefferkorn, J. Litchfield, 2014, Toxicologic pathology.

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Eliot Sugarman, Angel Guzman-Perez, G. S. Walker, 2011, ACS medicinal chemistry letters.

Development and evaluation of novel solid nanodispersion system for oral delivery of poorly water-soluble drugs.

M. Varma, J. Litchfield, A. El‐Kattan, 2013, Journal of controlled release : official journal of the Controlled Release Society.

Modeling Exposure to Understand and Predict Kidney Injury.

T. Maurer, A. Ghosh, J. Litchfield, 2019, Seminars in nephrology.

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif.

K. Gajiwala, M. Hickey, J. Pfefferkorn, 2013, Bioorganic & medicinal chemistry letters.

Discovery of Diphenylacetamides as CXCR7 Inhibitors with Novel β-Arrestin Antagonist Activity.

P. Loria, M. Boehm, Carina P. Tan, 2020, ACS medicinal chemistry letters.

pH-sensitive interaction of HMG-CoA reductase inhibitors (statins) with organic anion transporting polypeptide 2B1.

D. B. Duignan, B. Feng, T. Goosen, 2011, Molecular pharmaceutics.

Physiologically Based Modeling of Pravastatin Transporter-Mediated Hepatobiliary Disposition and Drug-Drug Interactions

B. Feng, T. Goosen, Y. Lai, 2012, Pharmaceutical Research.

Estimation of the Effect of OAT2-Mediated Active Uptake on Meloxicam Exposure in the Human Liver

J. Litchfield, H. Eng, S. Mathialagan, 2020, The AAPS Journal.

Identification of a novel conformationally constrained glucagon receptor antagonist.

S. Wright, A. Kalgutkar, J. Pfefferkorn, 2014, Bioorganic & medicinal chemistry letters.

Pathways of the Maillard Reaction In Vitro and In Vivo

J. Baynes, S. Thorpe, M. Wells-Knecht, 2005 .

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

A. Kalgutkar, J. Pfefferkorn, L. Di, 2015, Drug Metabolism and Disposition.

Predicting the Human Hepatic Clearance of Acidic and Zwitterionic Drugs.

A. Kalgutkar, M. Varma, J. Litchfield, 2020, Journal of medicinal chemistry.

Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies

A. Kalgutkar, D. Kazierad, A. Bergman, 2019, Xenobiotica; the fate of foreign compounds in biological systems.